Asarina Pharma issues new shares to Ergomed plc
(Stockholm, June 4, 2019) Asarina Pharma AB (publ) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 8 May 2019, issue 246,434 new shares to Ergomed plc (“Ergomed”), the CRO carrying out its Phase IIb PMDD study.The share issue has been triggered by the reaching of a planned milestone in the PMDD study, and it represents 1.5% of the current share capital in Asarina Pharma AB. Ergomed is responsible for the operational management of Asarina’s phase IIb study. As described in Asarina’s listing prospectus, dated 27 August 2018, Asarina and